Compare Redwire Corporation (RDW) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Redwire Corporation vs TransMedics Group Inc — how do they compare? Redwire Corporation trades at $9.53 (market cap $2.44B), while TransMedics Group Inc trades at $79.06 (market cap $2.74B). The key difference: Redwire Corporation and TransMedics Group Inc are close in size by market cap, and TransMedics Group Inc is more actively traded (949,331 versus 11,053,212). Which is the better fit depends on your goals — on Pluang, investors hold Redwire Corporation for 18 Days and TransMedics Group Inc for 24 Days on average.
| RDW | TMDX | |
|---|---|---|
Market Cap | $2.44B | $2.74B |
Volume | 11,053,212 | 949,331 |
Sector | Industrials | Health |
52-Week High | $25.90 | $150.42 |
52-Week Low | $5.06 | $61.99 |
Typical Hold Time | 18 Days | 24 Days |
Enterprise Value | $1.97B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Redwire Corporation (RDW) trades at $9.53, down 6.93% on the day, with technical indicators showing bearish momentum despite oversold RSI readings. The company reported negative earnings with Q2 2026 EPS of -$0.19 missing expectations, while revenue grew to $335.38M in 2025. Recent positive developments include a $981M Space Force contract award and partnerships with Honda and Sophia Space for robotics and orbital data centers.
Despite strong analyst support (80% buy ratings) and a $14.88 price target representing 56% upside, RDW faces significant fundamental challenges with negative profit margins and cash burn. The stock presents a high-risk opportunity for investors betting on space infrastructure growth, but requires careful monitoring of profitability improvements and execution on contract wins.
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
